Preventing the binding of pathogens to the host by controlling sphingolipid metabolism

Microbes and Infection

Volumn 8, Issue 3, 2006, Pages 938-945

  Radin, Norman S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Glycolipid depletion therapy; HIV 1; Pathogen binding to decoys; Protective adhesin therapy; Receptors and ligands

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; ADHESIN; ALGLUCERASE; ALPHA TOCOPHEROL; AMINOGLYCOSIDE DERIVATIVE; ANTIANDROGEN; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CHLORPROMAZINE; CHOLERA TOXIN; DESIPRAMINE; DOXORUBICIN; FANTOFARONE; GANGLIOSIDE GM3; GLOBOSIDE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; MIFEPRISTONE; N BUTYL DEOXYGALACTONOJIRIMYCIN; N BUTYL DEOXYNOJIRIMYCIN; RETINOL; SHIGA TOXIN; SIALIDASE; SPHINGOLIPID; TAMOXIFEN; TETANUS TOXIN; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

BINDING AFFINITY; BINDING SITE; BIOSYNTHESIS; CELL SURFACE; CHLAMYDIA; CLOSTRIDIUM PERFRINGENS; CONCENTRATION RESPONSE; DEPLETION; DIETARY INTAKE; DRUG MECHANISM; ESCHERICHIA COLI; GLYCOSYLATION; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; HERPES VIRUS; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFLUENZA VIRUS A; LIPID ANALYSIS; LIPID METABOLISM; LIPID RAFT; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RABIES VIRUS; ROTAVIRUS; SALMONELLOSIS; SENDAI VIRUS; SHORT SURVEY; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

BACTERIAL ADHESION; BACTERIAL TOXINS; HUMANS; SPHINGOLIPIDS; VIRUSES;

CHLAMYDIA; CLOSTRIDIUM PERFRINGENS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZAVIRUS A; RABIES VIRUS; ROTAVIRUS; SENDAI VIRUS;

EID: 33646021648     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2005.09.005     Document Type: Short Survey

References (72)

1. Ofek I., Hasty D.L., and Doyle R.J. Bacterial Adhesion to Animal Cells and Tissues (2003), ASM Press, Washington, DC
2. Schengrund C.L. "Multivalent" saccharides: development of new approaches for inhibiting the effects of glycosphingolipid-binding pathogens. Biochem. Pharmacol. 65 (2003) 699-707
3. Hansson G.C., Karlsson K.-A., Larson G., Stromberg N., and Thurin J. Carbohydrate-specific adhesion of bacteria to thin-layer chromatograms: a rationalized approach to the study of host cell glycolipid receptors. Anal. Biochem. 146 (1985) 158-163
4. Karlsson K.-A. Microbial recognition of target-cell glycoconjugates. Curr. Opin. Struct. Biol. 5 (1999) 622-635
5. Inokuchi J., and Radin N.S. Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of glucocerebroside synthetase. J. Lipid Res. 28 (1987) 565-571
6. Stapleton A.E., Stroud M.R., Hakomori S.I., and Stamm W.E. The globoseries glycosphingolipid sialosyl galactosyl globoside is found in urinary tract tissues and is a preferred binding receptor in vitro for uropathogenic Escherichia coli expressing pap-encoded adhesins. Infect. Immun. 66 (1998) 3856-3861
7. Svensson M., Lindstedt R., Radin N.S., and Svanborg C. Epithelial glucosphingolipid expression as a determinant of bacterial adherence and cytokine production. Infect. Immun. 62 (1994) 4404-4410
8. Abe A., Gregory S., Lee L., Killen P.D., Brady R.O., Kulkarni A., and Shayman J.A. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J. Clin. Invest. 105 (2000) 1563-1571
9. Inokuchi J.-I., Mason I., and Radin N.S. Antitumor activity in mice of an inhibitor of glycosphingolipid biosynthesis. Cancer Lett. 38 (1987) 23-30
10. Ferreira L., Villar E., and Munoz-Barroso I. Gangliosides and N-glycoproteins function as Newcastle disease virus receptors. Int. J. Biochem. Cell Biol. 36 (2004) 2344-2356
11. Bock K., Breimer M.E., Brignole A., Hansson G.C., Karlsson K.-A., Larson G., et al. Specificity of binding of a strain of uropathogenic Escherichia coli to Galα1→4Gal-containing glycosphingolipids. J. Biol. Chem. 260 (1985) 8545-8551
12. Jacewicz M.S., Acheson D.W., Binion D.G., West G.A., Lincicome L.L., Fiocchi C., and Keusch G.T. Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis. Infect. Immun. 67 (1999) 1439-1444
13. Guerrero C.A., Zarate S., Corkidi G., Lopez S., and Arias C.F. Biochemical characterization of rotavirus receptors in MA104 cells. J. Virol. 74 (2000) 9362-9371
14. Giguere J.F., and Tremblay M.J. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J. Virol. 78 (2004) 12062-12065
15. Svensson M., Frendeus B., Butters T., Platt F., Dwek R., and Svanborg C. Glycolipid depletion in antimicrobial therapy. Mol. MicroBiol. 47 (2003) 453-461
16. Andersson U., Smith D., Jeyakumar M., Butters T.D., Borja M.C., Dwek R.A., and Platt F.M. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. NeuroBiol. Dis. 16 (2004) 506-515
17. Deng W., Li R.X., Guerrera M., Liu Y.H., and Ladisch S. Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation. GlycoBiol. 12 (2002) 145-152
18. Liu Y.Y., Han T.Y., Yu J.Y., Bitterman A., Le A., Giuliano A.E., and Cabot M.C. Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. J. Lipid Res. 45 (2004) 933-940
19. Gouazé V., Yu J.Y., Bleicher R.J., Han T.Y., Liu Y.Y., Wang H., et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther. 3 (2004) 633-640
20. Shabbits J.A., and Mayer L.D. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol. Cancer Ther. 1 (2002) 205-213
21. De Rosa M.F., Sillence D., Ackerley C., and Lingwood C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem. 279 (2004) 7867-7876
22. Li W.Z., Watarai S., and Kodama H. Identification of glycosphingolipid binding sites for SEF21-fimbriated Salmonella enterica serovar Enteritidis in chicken oviductal mucosa. Veterinary MicroBiol. 93 (2003) 73-78
23. Margalit M., Ash N., Zimran A., and Halkin H. Enzyme replacement therapy in the management of longstanding skeletal and soft tissue Salmonella infection in a patient with Gaucher's disease. Postgrad. Med. J. 78 (2002) 564-565
24. Radin N.S. Infections and glycolipids, [Letter to Editor]. Postgrad. Med. J. 79 (2003) 185
25. Mizrachi Y., Lev M., Harish Z., Sundaram S.K., and Rubinstein A. L-cycloserine, an inhibitor of sphingolipid biosynthesis, inhibits HIV-1 cytopathic effects, replication, and infectivity. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11 (1996) 137-141
26. Hug P., Lin H.M., Korte T., Xiao X.D., Dimitrov D.S., Wang J.M., et al. Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J. Virol. 74 (2000) 6377-6385
27. Puri A., Rawat S.S., Lin H.M., Finnegan C.M., Mikovits J., Ruscetti F.W., and Blumenthal R. An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS 18 (2004) 849-858
28. Finnegan C.M., Rawat S.S., Puri A., Wang J.M., Ruscetti F.W., and Blumenthal R. Ceramide, a target for antiretroviral therapy, Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 15452-15457
29. Tamma S.L., Sundaram S.K., Lev M., and Coico R.F. Inhibition of sphingolipid synthesis down-modulates CD4 expression by peripheral blood T lymphocytes and T lymphoma cells. BioChem. Biophys. Res. Commun. 220 (1996) 916-921
30. Krifuks O., Bergelson L.D., and Schlesinger M. The down-modulation of CD4 induced by the GM1 ganglioside is regulated by phosphatases and kinases: evidence from enzyme inhibitors and anti-CD45 antibodies. Cell. Immunol. 187 (1998) 45-51
31. Shukla G.S., Shukla A., and Radin N.S. Gangliosides inhibit glucosylceramide synthase: possible role in ganglioside therapy. J. NeuroChem. 56 (1991) 2125-2132
32. Cabot M.C., Giuliano A.E., Volner A., and Han T.Y. Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett. 394 (1996) 129-131
33. Lavie Y., Cao H., Volner A., Lucci A., Han T.Y., Geffen V., et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem. 272 (1997) 1682-1687
34. Lucci A., Giuliano A.E., Han T.Y., Dinur T., Liu Y.Y., Senchenkov A., and Cabot M.C. Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int. J. Oncol. 15 (1999) 535-540
35. Hospattankar A.V., Vunnam R.R., and Radin N.S. Changes in liver lipids after administration of 2-decanoylamino-3-morpholinopropiophenone and chlorpromazine. Lipids 17 (1982) 538-543
36. Shukla A., Shukla G.S., and Radin N.S. Control of kidney size by sex hormones; possible involvement of glucosylceramide. Amer. J. Physiol. 262 (1992) F24-F29
37. Seo S.I., Lee S.J., Kim J.C., Choi Y.J., Woong S., Hwang T.K., and Cho Y.H. Effects of androgen deprivation on chronic bacterial prostatitis in a rat model. Int. J. Urol. 10 (2003) 485-491
38. Benten W.P., Wunderlich F., and Mossmann H.J. Testosterone-induced suppression of self-healing Plasmodium chabaudi malaria: an effect not mediated by androgen receptors?. Endocrinol. 135 (1992) 407-413
39. Zador I.Z., Deshmukh G.D., Kunkel R., Johnson K., Radin N.S., and Shayman J.A. A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J. Clin. Invest. 91 (1993) 797-803
40. Sundaram K.S., and Lev M. The long-term administration of L-cycloserine to mice: specific reduction of cerebroside level. NeuroChem. Res. 14 (1989) 245-248
41. Hickson-Bick D.L.M., Buja L.M., and McMillin J.B. Palmitate-mediated alterations in the fatty acid metabolism of rat neonatal cardiac myocytes. J. Mol. Cell. Cardiol. 32 (2000) 511-519
42. Andrieu-Abadie N., Jaffrézou J.P., Hatem S., Laurent G., Levade T., and Mercaider J.J. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J. 13 (1999) 1501-1510
43. Triola G., Fabrias G., Dragusin M., Niederhausen L., Broere R., and Llebaria A. G. van Echten-Deckert, Specificity of the dihydroceramide desaturase inhibitor N-[(1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanamide (GT11) in primary cultured cerebellar neurons. Mol. Pharmacol. 66 (2004) 1671-1678
44. Liu B., Andrieu-Abadie N., Levade T., Zhang P., Obeid L.M., and Hannun Y.A. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J. Biol. Chem. 273 (1998) 11313-11320
45. Schoeb T.R., Juliana M.M., Nichols P.W., Davis J.K., and Lindsey J.R. Effects of viral and mycoplasmal infections, ammonia exposure, vitamin A deficiency, host age, and organism strain on adherence of Mycoplasma pulmonis in cultured rat tracheas. Lab. Anim. Sci. 43 (1993) 417-424
46. Sharma S.A., Tummuru M.K., Blaser M.J., and Kerr L.D. Activation of IL-8 gene expression by H. pylori is regulated by transcription factor nuclear factor-kappa B in gastric epithelial cells. J. Immunol. 160 (1998) 2401-2407
47. Jeyakumar M., Smith D.A., Williams I.M., Borja M.C., Neville D.C., Butters T.D., et al. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann. Neurol. 56 (2004) 642-649
48. Metz R.J., and Radin N.S. Purification and properties of a cerebroside transfer protein. J. Biol. Chem. 257 (1982) 12901-12907
49. Yamada W., Abe A., and Sasaki T. Specificity of the glycolipid transfer protein from pig brain. J. Biol. Chem. 260 (1985) 4615-4621
50. Vanderjagt D.J., Fry D.E., and Glew R.H. Human glucocerebrosidase catalyses transglucosylation between GlcCer and retinol. Bioch. J. 300 (1994) 309-315
51. Kensinger R.D., Catalone B.J., Krebs F.C., Wigdahl B., and Schengrund C.L. Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection. Antimicrob. Agents Chemother 48 (2004) 1614-1623
52. Thompson J.P., and Schengrund C.L. Inhibition of the adherence of cholera toxin and the heat-labile enterotoxin of Escherichia coli to cell-surface GM1 by oligosaccharide-derivatized dendrimers. BioChem. Pharmacol 56 (1998) 591-597
53. Mamelak D., Mylvaganam M., Whetstone H., Hartmann E., Lennarz W., Wyrick P.B., et al. Hsp70s contain a specific sulfogalactolipid binding site. Differential aglycone influence on sulfogalactosyl ceramide binding by recombinant prokaryotic anti eukaryotic Hsp70 family members. BioChem. 40 (2001) 3572-3582
54. 3 interaction. J. Lipid Res. 43 (2002) 1670-1679
55. Suh M., Belosevic M., and Clandinin M.T. Dietary lipids containing gangliosides reduce Giardia muris infection in vivo and survival of Giardia lamblia trophozoites in vitro. Parasitology 128 (2004) 595-602
56. Shant J., Bhattacharyya S., Ghosh S., Ganguly N.K., and Majumdar S. A potentially important excretory-secretory product of Giardia lamblia. Exp. Parasitol. 102 (2002) 178-186
57. Stoll B.J., Holmgren J., Bardhan P.K., Huq I., Greenough III W.B., Fredman P., and Svennerholm L. Binding of intraluminal toxin in cholera: trial of GM1 ganglioside charcoal. Lancet 2 (1980) 888-891
58. Bernardi A., Arosio D., Manzoni L., Monti D., Posteri H., Potenza D., et al. Mimics of ganglioside GM1 as cholera toxin ligands: replacement of the GalNAc residue. J. Org. Biomol. Chem. 1 (2003) 785-792
59. Govoni V., Granieri E., Manconi M., and Capone J. I. Casetta, Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? a population-based study in the Local Health District of Ferrara, Italy. J. Neurol. Sci. 216 (2003) 99-103
60. Hosoya M., Balzarini J., Shigeta S., and De Clercq E. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob. Agents Chemother 35 (1991) 2515-2520
61. Delezay O., Hammache D., Fantini J., and Yahi N. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids. BioChem. 35 (1996) 15663-15671
62. Hammache D., Yahi N., Pieroni G., Ariasi F., Tamalet C., and Fantini J. Sequential interaction of CD4 and HIV-1 gp120 with a reconstituted membrane patch of ganglioside GM3: implications for the role of GSLs as potential HIV-1 fusion cofactors. BioChem. Biophys. Res. Commun. 246 (1998) 117-122
63. Speck R.R., Yu X.F., Hildreth J., and Flexner C. Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J. Infect. Dis. 186 (2002) 332-340
64. Superti F., and Donelli G. Characterization of SA-11 rotavirus receptorial structures on human colon carcinoma cell line HT-29. J. Med. Virol. 47 (1995) 421-428
65. Wang W., Cole A.M., Hong T., Waring A.J., and Lehrer R.I. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J. Immunol. 170 (2003) 4708-4716
66. Hakomori S. Carbohydrate-to-carbohydrate interaction in basic cell biology: a brief overview. Arch. Biochem. Biophys. 426 (2004) 173-181
67. Jonsson K., Guo B.P., Monstein H.J., Mekalanos J.J., and Kronvall G. Molecular cloning and characterization of two Helicobacter pylori genes coding for plasminogen-binding proteins. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 1852-1857
68. Radin N.S. Sphingolipids as coenzymes in anion transfer and tumor death. Bioorg. Med. Chem. 12 (2004) 6029-6037
69. Shimamoto S., Tamai E., Matsushita O., Minami J., Okabe A., and Miyata S. Changes in ganglioside content affect the binding of Clostridium perfringens epsilon-toxin to detergent-resistant membranes of Madin-Darby canine kidney cells. Microbiol. Immunol. 49 (2005) 245-253
70. Shen W.P., and Ladisch S. Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells. Cell. Immunol. 220 (2002) 125-133
71. Hinkovska-Galcheva V., Boxer L.A., Kindzelskii A., Hiraoka M., Akira A., Goparju S., et al. Ceramide-1-phosphate: a mediator of phagocytosis. J. Biol. Chem. 280 (2005) 26612-26621
72. Lauer S.A., Ghori N., and Haldar K. Sphingolipid synthesis as a target for chemotherapy against malaria parasites. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9181-9185